NCT02872259View on ClinicalTrials.gov

BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

February 13, 2017

Primary Completion Date

May 23, 2024

Study Completion Date

May 23, 2024

Conditions
Melanoma
Interventions
DRUG

BGB324+pembrolizumab

Combination

DRUG

BGB324+dabrafenib and trametinib

Combination

DRUG

pembrolizumab

Monotherapy

DRUG

dabrafenib and trametinib

Combination

Trial Locations (5)

1478

Akershus Univerisity Hospital, Lørenskog

5021

Haukeland University Hospital, Bergen

7006

St. Olavs Hospital, Trondheim

9038

University Hospital of North Norway, Tromsø

0424

Oslo University Hospital, Radiumhospitalet, Oslo

Sponsors

Collaborators (1)

BerGenBio ASA
All Listed Sponsors
collaborator

BerGenBio ASA

INDUSTRY

lead

Haukeland University Hospital

OTHER

NCT02872259 - BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma | Biotech Hunter | Biotech Hunter